合并肺部疾病对COVID-19严重程度的影响:系统综述与荟萃分析
该系统综述与荟萃分析通过五个国际检索库检索,最终纳入53项研究、658,073例患者,评估慢阻肺、哮喘及慢性呼吸系统疾病与COVID-19严重程度的关联。结果显示,慢阻肺和慢性呼吸系统疾病与更高的COVID-19严重程度相关,而哮喘与重症COVID-19无显著关联。
要点
- 合并慢阻肺的COVID-19患者重症风险升高(OR=2.58,95%CI 1.99-3.34)。
- 合并慢性呼吸系统疾病亦与重症COVID-19相关(OR=2.14,95%CI 1.74-2.64)。
- 哮喘与重症COVID-19无显著关联(OR=1.13,95%CI 0.79-1.60,p=0.50)。
核心结论
- 合并慢阻肺和慢性呼吸系统疾病与COVID-19严重程度升高明确相关。
- 哮喘与重症COVID-19之间未发现关联。
研究设计与样本
- 系统综述与荟萃分析,检索五个国际检索库,初检获722篇文献,最终纳入53项研究、658,073例患者。
主要发现
- 重症COVID-19患者中慢阻肺占比5.2%(2191/42,373),非重症中为1.4%(4203/306,151),随机效应模型OR=2.58,95%CI=1.99-3.34,Z=7.15,p<0.001。
- 重症COVID-19患者中慢性呼吸系统疾病占比8.6%(3780/44,041),非重症中为5.7%(16,057/280,447),随机效应模型OR=2.14,95%CI=1.74-2.64,Z=7.1,p<0.001。
- 重症COVID-19患者中哮喘占比2.3%(1873/81,319),非重症中为2.2%(11,796/538,737),随机效应模型OR=1.13,95%CI=0.79-1.60,Z=0.66,p=0.50。
临床怎么用
- 对合并慢阻肺或慢性呼吸系统疾病的COVID-19患者应关注其重症风险升高。
- 哮喘本身未显示与重症COVID-19的关联,临床评估需结合其他危险因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Coronavirus disease 2019 (COVID-19) caused by infection with severe acute respiratory syndrome coronavirus 2 was first detected in Wuhan, China, in late 2019 and continues to spread worldwide. Persistent questions remain about the relationship between the severity of COVID-19 and comorbid diseases, as well as other chronic pulmonary conditions. In this systematic review and meta-analysis, we aimed to examine in detail whether the underlying chronic obstructive pulmonary diseases (COPD), asthma and chronic respiratory diseases (CRDs) were associated with an increased risk of more severe COVID-19. A comprehensive literature search was performed using five international search engines. In the initial search, 722 articles were identified. After eliminating duplicate records and further consideration of eligibility criteria, 53 studies with 658,073 patients were included in the final analysis. COPD was present in 5.2% (2191/42,373) of patients with severe COVID-19 and in 1.4% (4203/306,151) of patients with non-severe COVID-19 (random-effects model; OR = 2.58, 95% CI = 1.99-3.34, Z = 7.15, p < 0.001). CRD was present in 8.6% (3780/44,041) of patients with severe COVID-19 and in 5.7% (16,057/280,447) of patients with non-severe COVID-19 (random-effects model; OR = 2.14, 95% CI = 1.74-2.64, Z = 7.1, p < 0.001). Asthma was present in 2.3% (1873/81,319) of patients with severe COVID-19 and in 2.2% (11,796/538,737) of patients with non-severe COVID-19 (random-effects model; OR = 1.13, 95% CI = 0.79-1.60, Z = 0.66, p = 0.50). In conclusion, comorbid COPD and CRD were clearly associated with a higher severity of COVID-19; however, no association between asthma and severe COVID-19 was identified.
引用
- Gülsen A, König IR, Jappe U, et al. Effect of comorbid pulmonary disease on the severity of COVID-19: A systematic review and meta-analysis. Respirology. 2021. PMID: 33955623. doi:10.1111/resp.14049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。